BIOMAT Database Logo BIOMAT Database Logo

Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. 2010

F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Department of Thoracic Oncology, Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan. foshita@kcch.jp

BACKGROUND Current international guidelines recommend the use of platinum-based chemotherapy with thoracic radiotherapy (TRT) for patients with locally advanced non-small-cell lung cancer (NSCLC). METHODS Patients with unresectable stage IIIA or IIIB NSCLC were treated with nedaplatin (NP) at 50 mg m(-2) and irinotecan (CPT) at 60 mg m(-2) on days 1 and 8 every 4 weeks for two to four cycles with concurrent TRT (2 Gy per day, total 60 Gy). RESULTS All 35 patients were able to receive a total of 60 Gy. Adverse effects and events in chemotherapy with TRT were grade 3 or 4 anaemia, neutropenia and thrombocytopenia, which occurred in 3.0%, 32.8% and 6.0% of patients, respectively. There was no grade 3 pneumonitis or oesophagitis. Adverse effects and events in chemotherapy alone were mild. There was no treatment-related death. An overall response rate was 94.3%. The median progression-free and overall survivals were 13.0 and 36.0 months, respectively. The 5-year disease-free and overall survival rates were 25.7% and 40.0%, respectively. CONCLUSIONS NP and CPT treatment with concurrent TRT is effective and safe for patients with unresectable, locally advanced NSCLC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077146 Irinotecan A semisynthetic camptothecin derivative that inhibits DNA TOPOISOMERASE I to prevent nucleic acid synthesis during S PHASE. It is used as an antineoplastic agent for the treatment of COLORECTAL NEOPLASMS and PANCREATIC NEOPLASMS. 7-Ethyl-10-hydroxycamptothecin,CPT 11,CPT-11,Camptosar,Camptothecin-11,Irinotecan Hydrochloride,Irrinotecan,NK012 Compound,SN 38,SN 38 11,SN-38,SN-38-11,7 Ethyl 10 hydroxycamptothecin,CPT11,Camptothecin 11,SN3811

Related Publications

F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Nedaplatin and irinotecan with concurrent thoracic radiotherapy followed by docetaxel consolidation in patients with locally advanced non-small cell lung cancer.
May 2017, Journal of experimental therapeutics & oncology,
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
November 2004, Japanese journal of clinical oncology,
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer.
December 2004, Journal of experimental therapeutics & oncology,
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer.
May 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
January 2021, The oncologist,
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma.
December 2005, International journal of clinical oncology,
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
March 1999, British journal of cancer,
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer.
July 2001, European journal of cancer (Oxford, England : 1990),
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
July 2019, Japanese journal of clinical oncology,
F Oshita, and M Ohe, and T Honda, and S Murakami, and T Kondo, and H Saito, and K Noda, and K Yamashita, and Y Nakayama, and K Yamada
Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
January 2017, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!